has invested in biotechnology company Earli to advance early cancer detection technologies. Facilitated through Accenture Ventures, the investment aims to enhance collaborations with global health and pharma companies, leveraging Earli’s synthetic targeting platform that reprogrammes cancer cells to aid in their detection and destruction. The gold standard of business intelligence.
Earli’s technology focuses on the early and accurate distinction between healthy and cancerous cells. The synthetic biopsy method is designed to improve the sensitivity and specificity of cancer detection, potentially leading to earlier diagnoses and more personalised treatment options. Earli’s technology is poised to revolutionise cancer detection by using non-invasive screening methods, such as blood samples and PET [positron emission topography] scans, to identify multiple cancer types.
The investment from Accenture Ventures is expected to help Earli expand its collaborations, potentially accelerating the development and availability of early cancer detection and treatment solutions. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Earli joins Accentur.